Human Respiratory Syncytial Virus Drugs Market Research Report covers the present scenario and the growth prospects of the Human Respiratory Syncytial Virus Drugs Industry for 2016-2020. Human Respiratory Syncytial Virus Drugs Market, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years and discussion of the key vendors effective in this market. To calculate the market size, the report considers the revenue generated from the sales of Human Respiratory Syncytial Virus Drugs globally.
For further information on this report, please visit- http://www.marketreportsworld.com/10293205
The Human Respiratory Syncytial Virus Drugs Market report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
Following Companies Are Key Players of the Human Respiratory Syncytial Virus Drugs Market:
- Teva Pharmaceutical
Other Prominent Vendors of Human Respiratory Syncytial Virus Drugs Market Are:
- ADMA Biologics
- Alnylam Pharmaceuticals
- Ark Biosciences
- Aviragen Therapeutics
- Bavarian Nordic
- Boehringer Ingelheim
“One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period. For instance, in January 2016, Mucosis received $4.1 million funding from the Wellcome Trust, a global charitable foundation focusing on improving health, to advance SynGEM, its proprietary intranasal RSV vaccine, into phase I and IIa human clinical trials. In September 2015, OrbiMed and Edmond de Rothschild Investment Partners co-led a $21 million series A round in ReViral, a London-based company that is developing RV521, a drug for the treatment of RSV. In June 2015, Immunovaccine commenced phase I clinical study of its DPX-RSV vaccine. The vaccine candidate contains a specific target and a viral protein that is active on the surface of infected cells. It is believed that an immune response to the specific target will limit the severity of RSV infection. The entry of new companies will certainly pave the way for the development of novel products for the treatment of RSV.”
Ask Sample PDF of Human Respiratory Syncytial Virus Drugs Market Report @ http://www.marketreportsworld.com/enquiry/request-sample/10293205
According to the Human Respiratory Syncytial Virus Drugs Market report, one driver in the market is presence of large patient pool fuels market growth. RSV is the leading cause of lower respiratory tract infections in infants and young children. Each year, 4-5 million children younger than four years of age acquire an RSV infection, and more than 0.12 million are hospitalized annually in the US because of this infection. For example, approximately 25 to 40 out of 100 individuals with RSV have signs or symptoms of pneumonia or bronchiolitis. Five to 20 out of 1,000 require hospitalization. Also, adults with compromised immune systems and of ages 65 and older are also at a higher risk of severe disease. In the US, on average, RSV leads to 57,257 hospitalizations among children of ages below 5 years; 2.1 million outpatient visits among children less than 5 years; and 0.17 million hospitalizations and 14,000 death cases among adults of ages more than 65 years. The presence of this large RSV patient pool with highly unmet medical needs with single approved therapy is expected to drive the market growth during the forecast period.
Report also presents Geographical Segmentation analysis of Human Respiratory Syncytial Virus Drugs Market of Americas, APAC, EMEA region.
For Any Query, Contact Our Expert @ http://www.marketreportsworld.com/enquiry/pre-order-enquiry/10293205
Further, the Human Respiratory Syncytial Virus Drugs Market report states that one challenge in the market is continuous change in guidelines from healthcare organizations impacts market growth. The dynamic nature of guidelines from the American Academy of Pediatrics Committee on Infectious Disease (AAPCID) restricted the patients eligible for preventive treatment with Synagis, the leading drug in the market. Synagis received US FDA approval in June 1998 for the treatment of lower respiratory infection caused by RSV. Since then, the AAPCID updated its guidance related to Synagis four times. The recent update (2014) states that the use of Synagis prophylaxis in infants and children should be restricted to those that are at increased risk of RSV infection. Earlier, the definition of high-risk children on the Synagis package was not included. Most payers in the US have implemented these guidelines in 2014.
Key questions answered in Human Respiratory Syncytial Virus Drugs market report:
- What will the Human Respiratory Syncytial Virus Drugs market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving Human Respiratory Syncytial Virus Drugs market?
- What are the challenges to Human Respiratory Syncytial Virus Drugs market growth?
- Who are the key vendors in Human Respiratory Syncytial Virus Drugs market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
No of Pages: 74
Price of Report: $ 2500 (Single User License)
Purchase Report @ http://www.marketreportsworld.com/purchase/10293205
About Market Reports World:
Market Reports World is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.
Mr. Ameya Pingaley
Market Reports World
+1 408 520 9750
Email – firstname.lastname@example.org